Extending human healthspan and longevity: a symposium report.

Autor: DeVito LM; Sticky Ink, Inc, New York, New York., Barzilai N; Albert Einstein College of Medicine, Bronx, New York., Cuervo AM; Albert Einstein College of Medicine, Bronx, New York., Niedernhofer LJ; University of Minnesota Medical School, Minneapolis, Minnesota., Milman S; Albert Einstein College of Medicine, Bronx, New York., Levine M; Yale School of Medicine, New Haven, Connecticut., Promislow D; University of Washington, Seattle, Washington., Ferrucci L; National Institute on Aging, National Institutes of Health, Bethesda, Maryland., Kuchel GA; University of Connecticut School of Medicine, Farmington, Connecticut., Mannick J; Life Biosciences, Boston, Massachusetts., Justice J; Wake Forest School of Medicine, Winston-Salem, North Carolina., Gonzales MM; University of Texas Health Sciences Center San Antonio, San Antonio, Texas., Kirkland JL; Mayo Clinic, Rochester, Minnesota., Cohen P; USC Leonard Davis School of Gerontology, Los Angeles, California., Campisi J; The Buck Institute for Research on Aging, Novato, California.; Lawrence Berkeley National Laboratory, Berkley, California.
Jazyk: angličtina
Zdroj: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2022 Jan; Vol. 1507 (1), pp. 70-83. Date of Electronic Publication: 2021 Sep 08.
DOI: 10.1111/nyas.14681
Abstrakt: For many years, it was believed that the aging process was inevitable and that age-related diseases could not be prevented or reversed. The geroscience hypothesis, however, posits that aging is, in fact, malleable and, by targeting the hallmarks of biological aging, it is indeed possible to alleviate age-related diseases and dysfunction and extend longevity. This field of geroscience thus aims to prevent the development of multiple disorders with age, thereby extending healthspan, with the reduction of morbidity toward the end of life. Experts in the field have made remarkable advancements in understanding the mechanisms underlying biological aging and identified ways to target aging pathways using both novel agents and repurposed therapies. While geroscience researchers currently face significant barriers in bringing therapies through clinical development, proof-of-concept studies, as well as early-stage clinical trials, are underway to assess the feasibility of drug evaluation and lay a regulatory foundation for future FDA approvals in the future.
(© 2021 New York Academy of Sciences.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje